In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology

Set Alert for Oncology

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

BioPharmaceutical Growth Business Strategies

Innovation In Oncology: An Infographic

Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails. (Free article.)

BioPharmaceutical Cancer Research and Development Strategies
Advertisement

CAR-T Commercialization Strategies: Views From Novartis And Kite

At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.

Regenerative Medicine Commercial Cancer

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals ImmunoOncology

Oncology Disruption Demands Strategic Transformation

The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.

BioPharmaceutical Business Strategies Cancer

Inside Bayer Oncology: An Interview With Robert LaCaze

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

Business Strategies Deals BioPharmaceutical

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?

With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.

BioPharmaceutical Cancer Innovation

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Business Strategies Cancer BioPharmaceutical

Free And Open: The Next Wave In Clinical Trial Data?

Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.

Clinical Trials Platform Technologies BioPharmaceutical

When Two Worlds Collide – BTG Brings Interventional Oncology And Immunotherapy Together

BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.

ImmunoOncology Research and Development Strategies Cancer

Finding The Right Path To Category Leadership In Oncology

Oncology drug development is undergoing rapid shifts. Bain research shows companies that seek to lead in specific vertical categories outperform rivals that invest across a broad spectrum of cancer targets.

Business Strategies Growth Cancer

Schilsky On ASCO 2017: The “You” Factor In Cancer Care

ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.

BioPharmaceutical Cancer Market Access

CAR-T Cancer Drugs Front And Center At ARM Investor Day

Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.

Regenerative Medicine Commercial Cancer

Combinations Continue To Drive Immuno-Oncology Deal-Making

The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.

Deals ImmunoOncology Cancer

More on Oncology from Scrip, Pink Sheet & Medtech Insight.

Two Hopefuls And A ‘No’: EMA Decisions On Accelerated Access

Regeneron and Shire should find out this week whether the European Medicines Agency will agree to fast-track its review of their products.

Drug Review Europe

Roche To Build RWE Cancer Data Extraction Role With Flatiron Buy

Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.

Business Strategies Commercial

Exploring Sanofi's Revamped IO Pipeline

In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.

Business Strategies ImmunoOncology

QUOTED. Feb. 9, 2018. Matt Anderson.

Check out what Medtronic's Matt Anderson had to say about the goals of a new lung-cancer collaboration between his firm and Philips Healthcare.
Quoted Commercial

Philips, Medtronic Seek To Navigate Lung Cancer Patients Toward Better Care

The two medtech leaders announced a partnership to develop and commercialize the LungGPS patient management platform, originally developed by superDimension and acquired by Medtronic in the Coviden merger. The patient and data management platform helps track and manage patients diagnosed with lung nodules, from identifying the nodules on images, through diagnosis, treatment, and long-term survivorship.

Diagnostic Imaging Cancer

SOPHiA Genetics Combines In Vivo And In Vitro Cancer Analyses With Enhanced AI Platform

Clinical genomics company SOPHiA Genetics is integrating new radiomics capabilities to enhance its artificial intelligence (AI) platform SOPHiA, which is already used for analyses of oncology data from liquid biopsy tests. The news marks an increasing trend toward integrating in vivo and in vitro data onto a single diagnostic platform.

Cancer Artificial Intelligence
UsernamePublicRestriction

Register